<DOC>
	<DOCNO>NCT00676988</DOCNO>
	<brief_summary>To assess relationship change Crohn 's Disease Activity Index ( CDAI ) score trough serum infliximab concentration subject schedule receive infliximab infusion interval 8 week .</brief_summary>
	<brief_title>Study Determine Relationship Between Serum Infliximab Efficacy Luminal Crohn 's Disease Patients</brief_title>
	<detailed_description>This cross sectional study evaluate sample 360 subject luminal Crohn 's disease receive infliximab 15-20 Canadian infusion centre . The sample stratify disease activity [ mild = CDAI &lt; 150 , moderate/severe = CDAI â‰¥150 ] whether subject concomitant immunosuppressive therapy . Thus 4 stratum create consist 90 subject . Consent obtain prior Visit 1 , subject retrospectively complete CDAI diary card precede 7 day blood work drawn prior infliximab infusion . Four week thereafter Visit 2 , subject provide additional blood sample measure serum infliximab concentration CRP level . Between Visits 1 3 , subject complete daily CDAI diary entry . Visit 3 take place next schedule infusion , 8 week Visit 1 ( +/- 7 day ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult subject ( 18 year age old time consent ) Confirmed diagnosis inflammatory luminal Crohn 's Disease Receive infliximab therapy receive minimum 5 consecutive infusion prescribe interval ( minimum 24 week maximum 156 week infliximab therapy ) Plan receive next 2 infliximab infusion 8weekly interval ( +/ 7 day ) Able provide write consent Active drain fistulizing Crohn 's Disease Presence ostomy Diagnosis ulcerative colitis Infliximab dose &gt; 5mg/kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Luminal Crohn 's Disease</keyword>
	<keyword>Infliximab</keyword>
</DOC>